JP2020515249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515249A5 JP2020515249A5 JP2019552556A JP2019552556A JP2020515249A5 JP 2020515249 A5 JP2020515249 A5 JP 2020515249A5 JP 2019552556 A JP2019552556 A JP 2019552556A JP 2019552556 A JP2019552556 A JP 2019552556A JP 2020515249 A5 JP2020515249 A5 JP 2020515249A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- muc1
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 7
- 102100034256 Mucin-1 Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 239000000611 antibody drug conjugate Substances 0.000 claims 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000699800 Cricetinae Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 241000588770 Proteus mirabilis Species 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000228257 Aspergillus sp. Species 0.000 claims 1
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000235058 Komagataella pastoris Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000589774 Pseudomonas sp. Species 0.000 claims 1
- 241000235070 Saccharomyces Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 241001147693 Staphylococcus sp. Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 241000187180 Streptomyces sp. Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158852A JP7158547B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
| JP2021158853A JP7158548B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0035622 | 2017-03-21 | ||
| KR20170035622 | 2017-03-21 | ||
| KR1020180032592A KR102127421B1 (ko) | 2017-03-21 | 2018-03-21 | Muc1에 특이적으로 결합하는 항체 및 그의 용도 |
| PCT/KR2018/003267 WO2018174544A2 (ko) | 2017-03-21 | 2018-03-21 | Muc1에 특이적으로 결합하는 항체 및 그의 용도 |
| KR10-2018-0032592 | 2018-03-21 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158852A Division JP7158547B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
| JP2021158853A Division JP7158548B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515249A JP2020515249A (ja) | 2020-05-28 |
| JP2020515249A5 true JP2020515249A5 (cg-RX-API-DMAC7.html) | 2020-07-30 |
| JP7032425B2 JP7032425B2 (ja) | 2022-03-08 |
Family
ID=63877998
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552556A Active JP7032425B2 (ja) | 2017-03-21 | 2018-03-21 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
| JP2021158852A Active JP7158547B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
| JP2021158853A Active JP7158548B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158852A Active JP7158547B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
| JP2021158853A Active JP7158548B2 (ja) | 2017-03-21 | 2021-09-29 | Ｍｕｃ１に特異的に結合する抗体及びその用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11472887B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3825328A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7032425B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102127421B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111201240B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018238165C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019019650A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3056582C (cg-RX-API-DMAC7.html) |
| IL (1) | IL269488B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019011101A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2746413C1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201906813B (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11472887B2 (en) | 2017-03-21 | 2022-10-18 | Peptron, Inc. | Antibody binding specifically to MUC1 and use thereof |
| CA3141926A1 (en) | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| US20230085269A1 (en) * | 2020-03-18 | 2023-03-16 | Biomodifying, Llc | Anti- muc1-sea antibodies |
| KR102811084B1 (ko) * | 2020-12-24 | 2025-05-23 | 주식회사 엘지화학 | 뮤신 1에 특이적인 폴리펩티드 및 이의 이용 |
| KR20240049858A (ko) * | 2021-07-30 | 2024-04-17 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 항체-약물 접합체 및 이의 사용방법 |
| AU2022333837A1 (en) | 2021-08-27 | 2024-03-14 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
| CN114028539B (zh) * | 2021-09-13 | 2024-04-26 | 北京大学 | 粘蛋白1在抑制冠状病毒中的应用 |
| CN114106110B (zh) * | 2021-11-25 | 2025-04-18 | 国家纳米科学中心 | 一种特异性结合muc1蛋白的多肽、靶向载药共递送系统及其制备方法与应用 |
| EP4471066A4 (en) * | 2022-01-24 | 2025-10-01 | Cyron Therapeutics Co Ltd | ANTIBODIES SPECIFICALLY BINDING TO MUC-1 AND USES THEREOF |
| CN116554317B (zh) * | 2022-01-29 | 2025-02-28 | 浙江纳米抗体技术中心有限公司 | Muc1结合分子及其应用 |
| CN119317447A (zh) * | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| AU2024207058A1 (en) * | 2023-01-09 | 2025-06-26 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-egfr/muc1 antibodies and uses thereof |
| AR132043A1 (es) * | 2023-03-03 | 2025-05-21 | Beigene Switzerland Gmbh | Anticuerpos muc1 y métodos de uso |
| CN120813609A (zh) * | 2023-03-03 | 2025-10-17 | 广州百济神州生物制药有限公司 | Muc1和cd16a抗体及使用方法 |
| AU2024251169A1 (en) * | 2023-04-13 | 2025-10-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to egfr and muc1, drug conjugate thereof, and medical use thereof |
| WO2025026358A1 (zh) * | 2023-08-01 | 2025-02-06 | 浙江纳米抗体技术中心有限公司 | Muc1结合分子和包含其的嵌合抗原受体 |
| WO2025080693A1 (en) * | 2023-10-11 | 2025-04-17 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
| WO2025218621A1 (zh) * | 2024-04-15 | 2025-10-23 | 原启生物科技(上海)有限责任公司 | 靶向muc1的抗原结合蛋白 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60140461D1 (de) * | 2000-09-11 | 2009-12-24 | Genzyme Corp | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
| JP2005508839A (ja) * | 2001-03-29 | 2005-04-07 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ペプチドおよびｍｕｃ１タンパク質に対する抗体 |
| US8129506B2 (en) * | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| WO2011007961A2 (en) | 2009-07-17 | 2011-01-20 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| JP6908381B2 (ja) | 2014-01-29 | 2021-07-28 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体 |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| US11472887B2 (en) | 2017-03-21 | 2022-10-18 | Peptron, Inc. | Antibody binding specifically to MUC1 and use thereof |
-
2018
- 2018-03-21 US US16/495,373 patent/US11472887B2/en active Active
- 2018-03-21 KR KR1020180032592A patent/KR102127421B1/ko active Active
- 2018-03-21 JP JP2019552556A patent/JP7032425B2/ja active Active
- 2018-03-21 CN CN201880026127.7A patent/CN111201240B/zh active Active
- 2018-03-21 EP EP20212863.3A patent/EP3825328A1/en active Pending
- 2018-03-21 MX MX2019011101A patent/MX2019011101A/es unknown
- 2018-03-21 EP EP18771928.1A patent/EP3604334A4/en active Pending
- 2018-03-21 IL IL269488A patent/IL269488B2/en unknown
- 2018-03-21 AU AU2018238165A patent/AU2018238165C1/en active Active
- 2018-03-21 BR BR112019019650-1A patent/BR112019019650A2/pt unknown
- 2018-03-21 CA CA3056582A patent/CA3056582C/en active Active
- 2018-03-21 RU RU2019132900A patent/RU2746413C1/ru active
-
2019
- 2019-10-16 ZA ZA2019/06813A patent/ZA201906813B/en unknown
-
2020
- 2020-06-22 KR KR1020200075680A patent/KR102169224B1/ko active Active
- 2020-12-04 AU AU2020281132A patent/AU2020281132B2/en active Active
- 2020-12-04 AU AU2020281130A patent/AU2020281130B2/en active Active
- 2020-12-09 US US17/116,265 patent/US11718684B2/en active Active
-
2021
- 2021-09-29 JP JP2021158852A patent/JP7158547B2/ja active Active
- 2021-09-29 JP JP2021158853A patent/JP7158548B2/ja active Active
-
2022
- 2022-07-11 US US17/811,845 patent/US11739158B2/en active Active
- 2022-07-12 US US17/811,904 patent/US11739159B2/en active Active